Search

Your search keyword '"Bhargava, Manorama"' showing total 196 results
Start Over Author "Bhargava, Manorama"
196 results on '"Bhargava, Manorama"'

16. Aspirin and clopidogrel resistance in Indian patients with ischemic stroke and its associations with gene polymorphisms: A pilot study

Author

Patel, Samir, Arya, Vandana, Saraf, Amrita, Bhargava, Manorama, and Agrawal, C.

Subjects
Dosage and administration, Research, Drug therapy, Health aspects, Clopidogrel -- Dosage and administration, Aspirin -- Dosage and administration, Drug resistance -- Research, Stroke -- Drug therapy, Stroke patients -- Health aspects, Genetic polymorphisms -- Research, EDTA, Recurrence (Disease), Genes, Ischemia, Genetic research
Published
2019

36. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma

Author

Raina, Vinod, Sharma, Atul, Kumar, Rajive, and Bhargava, Manorama

Subjects
Multiple myeloma -- Care and treatment, Melphalan -- Health aspects, Granulocyte colony-stimulating factor -- Health aspects, Blood transfusion, Autologous -- Health aspects, Health
Published
1996

40. Prasugrel resistance and impact of select gene variants in Indian patient with coronary artery disease

Author

Mohanty, Arun, primary, Arya, Vandana, additional, Singh Sawhney, Jitendra Pal, additional, Saraf, Amrita, additional, Bhargava, Manorama, additional, Jain, Rajneesh, additional, Passey, Rajeev, additional, Mehta, Ashwani, additional, Mantri, Raja Ram, additional, Makhija, Aman, additional, Khandpal, Bhuvanesh, additional, and Madan, Kushal, additional

Published
2018
Full Text
View/download PDF

47. Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab

Author

Kumar, Jeevan, Bhargava, Manorama, and Aggarwal, Shyam

Subjects
Article Subject, digestive system diseases
Abstract

We report a case of bevacizumab- (BEV-) induced thrombocytopenia in a 59-year-old man with adenocarcinoma of colon. After colectomy, the patient was treated with twelve cycles of FOLFOX-4 (folinic acid, 5-fluorouracil, and oxaliplatin) regimen. On relapse, he was treated with FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) regimen along with BEV 10 mg/kg for 6 cycles. After that, BEV was continued for maintenance as a single agent at an interval of three weeks. After the13th cycle of BEV, the patient developed melena with epistaxis and thrombocytopenia, from which he recovered on withdrawal of BEV. On rechallenge with half the initial dose, there was once again a reversible drop in platelet count. The proposed mechanism of thrombocytopenia may be immune-mediated peripheral destruction of platelets.

Published
2012
Full Text
View/download PDF

49. Spectrum of Monoclonal Light-Chain Gammopathy in a Tertiary Care Hospital.

Author

Zafar, Mir Sadaqat Hassan, Sinha, Swasti, Aggarwal, Shyam, and Bhargava, Manorama

Subjects
MONOCLONAL gammopathies, TERTIARY care, PLASMA cell diseases, ANEMIA, ACUTE kidney failure
Abstract

Background: Monoclonal light chain gammopathies are uncommon subsets of plasma cell disorders which usually present as diagnostic challenge. Materials and Methods: Twenty cases of monoclonal light-chain gammopathy were identified after screening 150 plasma cell disorders at a tertiary care referral center of North India and were analyzed for clinical profile and treatment outcomes. Results: Out of 20 cases of monoclonal light-chain gammopathy, 65% (13/20) were light-chain multiple myeloma (LCMM) type, 20% (4/20) were light-chain deposition disease (LCDD) type, and 15% (3/20) had primary amyloidosis (AL). Renal failure (65% of cases) was the most common presentation. All the patients with LCDD presented with renal failure (4/4) while as 61% of LCMM (8/13) and 33% of AL (1/3) presented with renal failure. Five patients presented with anemia and all were LCMM type. Two patients presented with lytic bone lesions (LCMM type) and one patient presented with plasmacytoma (LCMM). Overall response rate after 4 cycles of induction therapy was 92.3% in LCMM group, 100% in LCDD group, and 33.33% in AL group (excluding one patient who expired before the start of treatment). LCMM showed 23% partial remission (PR), 30.77% very good PR, 38.46% complete response (CR), and 5% no response (NR). LCDD showed PR 75% and CR 25%. AL showed PR 33.33% and NR 5%. Conclusions: Renal failure is a common presentation of monoclonal light chain gammopathies, and it should alert the treating physician for the underlying uncommon plasma cell disorder. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results